lometrexol
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2001 (NCT00024310)
Timeline
Indications
Mechanism of action
- GAR transformylaseINHIBITOR
GART inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc2c(c(=O)[nH]1)C[C@@H](CCc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2- Mol. weight
- 443.46 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL34412 ↗
Also known as
- 5,10-ddtf
- 5,10-dideaza-5,6,7,8-tetrahydrofolic acid
- 5,10-dideazatetrahydrofolate
- 5,10-dideazatetrahydrofolic acid
- ddathf
- lometrexol
- lometrexol
- lometrexol
- lometrexol
- lometrexol, (6r)-isomer
- lometrexol, (6s)-isomer
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00033722 | Phase 2 | Feb 1, 2002 | Tularik |
| NCT00024310 | Phase 1 | Sep 1, 2001 | National Cancer Institute (NCI), University of California, Los Angeles |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2001 |
| Tularik | For profit | 1 | 1 | 1 | 2002 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2001 |
3 organizations
Page 1 / 1